Hypersensitivity News and Research

RSS

Hypersensitivity is an exaggerated response by the immune system to a drug or other substance.

Vaccine-related chronic fatigue syndrome in an individual demonstrating aluminium overload

A team of scientists have investigated a case of vaccine-associated chronic fatigue syndrome (CFS) and macrophagic myofasciitis in an individual demonstrating aluminium overload.

18 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Genetic screening effective for initial HIV treatment

A major study from a team of researchers from Weill Cornell Medical College and Massachusetts General Hospital has found that a recent change to HIV-treatment guidelines recommending genetic screening is cost-effective under certain conditions. The new recommendation suggests conducting a genetic screening test prior to prescribing the drug abacavir, one of the preferred first-line drugs for the treatment for HIV-infected adults.

17 Sep 2008

Wheezing after early-life antibiotics: Blame the underlying chest infection more than the antibiotics

Children who are given antibiotics in their first three months often wheeze at 15 months of age. However, this wheezing is probably more due to the presence of chest infections than to the use of antibiotics.

6 Aug 2008

Alcohol linked to increased risk of perennial allergic rhinitis

There is a link between alcohol consumption and increased risk of perennial allergic rhinitis, according to a recent Danish study of 5,870 young adult women.

29 Jul 2008

Watson Pharmaceuticals launches generic version of dronabinol

Watson Pharmaceuticals, Inc. has announced that, under a supply agreement with Solvay Pharmaceuticals, Inc., Watson has launched the authorized generic version of dronabinol in the 2.5, 5 and 10 mg once daily dosage strengths.

30 Jun 2008

FDA approves Kinrix - combination vaccine for diphtheria, tetanus, pertussis and polio diseases in one shot

GlaxoSmithKline has announced that the U.S. Food and Drug Administration (FDA) has approved Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], the first combination vaccine to offer protection against diphtheria, tetanus, pertussis and polio diseases in one shot.

24 Jun 2008

FDA lifts clinical hold on Genta's Tesetaxel

Genta Incorporated announced that the Company has received notification from the U.S. Food and Drug Administration (FDA) that Genta may resume clinical trials with tesetaxel, a leading oral taxane in Genta's oncology product portfolio.

23 Jun 2008

Irritable bowel syndrome linked to chilli pepper pain receptor

People with irritable bowel syndrome have a higher than usual number of chilli pepper pain receptors, according to a new study published tomorrow (Wednesday 11 June).

10 Jun 2008

Researchers highlight distinct subtypes of myalgic encephalomyelitis

Researchers have identified distinct subtypes of myalgic encephalomyelitis (ME/CFS - also referred to as chronic fatigue syndrome) and there is renewed hope that treatments are available for this debilitating neurological illness.

7 May 2008

Mould in the home

Surely your bathroom is fungus-free once you've wiped the mould off the tiles? Not according to a study by French scientists in the Royal Society of Chemistry's Journal of Environmental Monitoring. They report that almost one in five rooms studied with no visible mould was in fact "highly contaminated" by fungus which could aggravate conditions such as asthma.

30 Apr 2008

Biomarkers identified for idiopathic pulmonary fibrosis

The first evidence of a distinctive protein signature that could help to transform the diagnosis and improve the monitoring of the devastating lung disease idiopathic pulmonary fibrosis (IPF) is being reported by University of Pittsburgh School of Medicine researchers in this month's edition of PLoS Medicine, an open-access journal of the Public Library of Science.

28 Apr 2008

FDA approves Actonel (risedronate sodium) for postmenopausal osteoporosis

The U.S. Food and Drug Administration (FDA) approved a new once-a-month dose (150 mg) of Actonel (risedronate sodium) tablets for the treatment and prevention of postmenopausal osteoporosis. Actonel is approved to reduce the risk of fractures in postmenopausal women with osteoporosis.

24 Apr 2008

Tredaptive and Janumet recommended for approval in European Union

Food and Drug Administration (FDA) is currently reviewing the combination of extended release (ER) niacin and laropiprant under the trademark Cordaptive (ER niacin/laropiprant). The CHMP recommendation does not apply to regulatory decisions by the FDA and no inferences should be made about pending FDA regulatory actions based on the recommendation of the CHMP.

24 Apr 2008

U.S. and China at loggerheads over contaminated Heparin

Health officials in the U.S. appear to be at loggerheads with Chinese officials over the contamination of the blood-thinning drug Heparin.

22 Apr 2008

Biomarkers allow doctors to match therapy to patient

Genetic variations ensure that no two people are exactly alike, nor are their cancers.

13 Apr 2008

Cancer drug allergies

Cancer patients from the Southeastern United States who are treated with the drug cetuximab, known commercially as Erbitux, are far more likely to suffer severe allergic reactions than patients in other regions of the country.

14 Mar 2008

Researchers find cause of severe allergic reaction to cetuximab

Clinicians have been perplexed by the fact that some patients given the drug cetuximab - an immune-based therapy commonly used to treat persons diagnosed with head and neck cancer, or colon cancer - have a severe and rapid adverse reaction to the drug.

13 Mar 2008

Myostatin shows promise for muscular dystrophy

Myostatin, a protein that blocks muscle growth, has shown promising results as a potential therapeutic target for treating muscular dystrophy in animal studies, where its inhibition led to increased muscle mass and strength.

12 Mar 2008

FDA approves Aloxi injection for prevention of postoperative nausea and vomiting

Eisai Corporation of North America, its U.S. subsidiary, MGI PHARMA, INC., and Helsinn Healthcare SA today announced that the U.S. Food and Drug Administration (FDA) has approved Aloxi (palonosetron hydrochloride) injection for the prevention of postoperative nausea and vomiting (PONV) for up to 24 hours following surgery.

4 Mar 2008